There is a lack of knowledge among patients concerning their treatment with bDMARDs. To increase knowledge and safety skills, patient education is essential. The aim of this study is to assess the impact of a pharmacist's educational interview on on knowledge and safety skills to bDMARDs in patients with inflammatory arthritis.
This is an observational, controlled, open-label and monocentric study. 60 patients are planned to be included. Knowledge are assessed three time by self-administered questionnaire: at baseline before the pharmacist's educational interview at three months apart at six months apart One primary end-point is defined: the changes from baseline to M3 and M6 in the patients' knowledge score about subcutaneous bDMARD management (self-administered questionnaire, Biosecure) As secondary end-points, the changes from baseline to M3 and M6 in patients' adherence, patients' satisfaction regarding the pharmacists' intervention and the effect of the interview on rate of patients treated by biosimilar are evaluated.
Study Type
OBSERVATIONAL
Enrollment
60
Information about bDMARDs management.
Hôpital Cochin
Paris, France
RECRUITINGChange in bDMARDS knowledge and skills at 3 and 6 months in patients who received a pharmaceutical consultation
Knowledge level and score comparison (good or moderate or bad knowledge) evaluated by self-questionnaire (Biosecure) from baseline to M3 and M6 after the pharmaceutical consultation. Biosecure : Minimum = 0 ; Maximum = 100 Good knowledge \> 84 Moderate knoledge : 64 to 84 Bad knowledge \< 64 Higher scores mean a better outcome.
Time frame: 6 months of follow-up
Change in bDMARDS adherence at 3 and 6 months in patients who received a pharmaceutical consultation
Adherence level comparison (high or low adherence) evaluated by self-questionnaire, Compliance Questionnaire for Rheumatology (CQR-5) from baseline to M3 and M6 after the consultation. High adherence means a better outcome.
Time frame: 6 months of follow-up
Satisfaction of patients on the pharmaceutical interview 3 months apart
Assessment of patients' satisfaction on the pharmaceutical interview at 3 months of the consultation.
Time frame: 3 months of follow-up
Change in rate of patients treated by biosimilar after the pharmaceutical consultation
Comparison of patient treated by biosimilar rate from baseline to M3 and M6 after the consultation
Time frame: 6 months of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.